Industry Research Reports

Home > Reports > Service & Software > Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Service & Software

Published Date: 2025-03-12

Pages: 138 Pages

Report ld: 4649172

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.

North American market for Oligonucleotide Drug CDMO Services was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Oligonucleotide Drug CDMO Services was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Oligonucleotide Drug CDMO Services was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global key companies of Oligonucleotide Drug CDMO Services include Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma, Cytiva, TriLink BioTechnologies, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Drug CDMO Services, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Drug CDMO Services by region & country, by Type, and by Application.

The Oligonucleotide Drug CDMO Services market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Drug CDMO Services.

MARKET SEGMENTATION

By Company

Bachem
WuXi TIDES
Ajinomoto Co
Waters
AGC Biologics
Merck KGaA
EUROAPI
CordenPharma
Cytiva
TriLink BioTechnologies
Medicilon
General Biol
BioSpring
Bio-Synthesis Inc
Aurisco
Suzhou Olipharma Co.,Ltd
Porton
RIBOPharm

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

API
Preparation

Segment by Application

SME Pharmaceutical Company
Large Pharmaceutical Company

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oligonucleotide Drug CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Oligonucleotide Drug CDMO Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Oligonucleotide Drug CDMO Services in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Oligonucleotide Drug CDMO Services Product Introduction

1.2 Global Oligonucleotide Drug CDMO Services Market Size Forecast (2020-2031)

1.3 Oligonucleotide Drug CDMO Services Market Trends & Drivers

1.3.1 Oligonucleotide Drug CDMO Services Industry Trends

1.3.2 Oligonucleotide Drug CDMO Services Market Drivers & Opportunity

1.3.3 Oligonucleotide Drug CDMO Services Market Challenges

1.3.4 Oligonucleotide Drug CDMO Services Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Oligonucleotide Drug CDMO Services Players Revenue Ranking (2024)

2.2 Global Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025)

2.3 Key Companies Oligonucleotide Drug CDMO Services Manufacturing Base Distribution and Headquarters

2.4 Key Companies Oligonucleotide Drug CDMO Services Product Offered

2.5 Key Companies Time to Begin Mass Production of Oligonucleotide Drug CDMO Services

2.6 Oligonucleotide Drug CDMO Services Market Competitive Analysis

2.6.1 Oligonucleotide Drug CDMO Services Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by Oligonucleotide Drug CDMO Services Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drug CDMO Services as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 API

3.1.2 Preparation

3.2 Global Oligonucleotide Drug CDMO Services Sales Value by Type

3.2.1 Global Oligonucleotide Drug CDMO Services Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Oligonucleotide Drug CDMO Services Sales Value, by Type (2020-2031)

3.2.3 Global Oligonucleotide Drug CDMO Services Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 SME Pharmaceutical Company

4.1.2 Large Pharmaceutical Company

4.2 Global Oligonucleotide Drug CDMO Services Sales Value by Application

4.2.1 Global Oligonucleotide Drug CDMO Services Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Oligonucleotide Drug CDMO Services Sales Value, by Application (2020-2031)

4.2.3 Global Oligonucleotide Drug CDMO Services Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global Oligonucleotide Drug CDMO Services Sales Value by Region

5.1.1 Global Oligonucleotide Drug CDMO Services Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Oligonucleotide Drug CDMO Services Sales Value by Region (2020-2025)

5.1.3 Global Oligonucleotide Drug CDMO Services Sales Value by Region (2026-2031)

5.1.4 Global Oligonucleotide Drug CDMO Services Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

5.2.2 North America Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

5.3.2 Europe Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

5.4.2 Asia Pacific Oligonucleotide Drug CDMO Services Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

5.5.2 South America Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

5.6.2 Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Oligonucleotide Drug CDMO Services Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.3 United States

6.3.1 United States Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.3.2 United States Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Oligonucleotide Drug CDMO Services Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.4.2 Europe Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Oligonucleotide Drug CDMO Services Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.5.2 China Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

6.5.3 China Oligonucleotide Drug CDMO Services Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.6.2 Japan Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Oligonucleotide Drug CDMO Services Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.7.2 South Korea Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Oligonucleotide Drug CDMO Services Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.8.2 Southeast Asia Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Oligonucleotide Drug CDMO Services Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Oligonucleotide Drug CDMO Services Sales Value, 2020-2031

6.9.2 India Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

6.9.3 India Oligonucleotide Drug CDMO Services Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Bachem

7.1.1 Bachem Profile

7.1.2 Bachem Main Business

7.1.3 Bachem Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.1.4 Bachem Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.1.5 Bachem Recent Developments

7.2 WuXi TIDES

7.2.1 WuXi TIDES Profile

7.2.2 WuXi TIDES Main Business

7.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.2.4 WuXi TIDES Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.2.5 WuXi TIDES Recent Developments

7.3 Ajinomoto Co

7.3.1 Ajinomoto Co Profile

7.3.2 Ajinomoto Co Main Business

7.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.3.4 Ajinomoto Co Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.3.5 Ajinomoto Co Recent Developments

7.4 Waters

7.4.1 Waters Profile

7.4.2 Waters Main Business

7.4.3 Waters Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.4.4 Waters Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.4.5 Waters Recent Developments

7.5 AGC Biologics

7.5.1 AGC Biologics Profile

7.5.2 AGC Biologics Main Business

7.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.5.4 AGC Biologics Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.5.5 AGC Biologics Recent Developments

7.6 Merck KGaA

7.6.1 Merck KGaA Profile

7.6.2 Merck KGaA Main Business

7.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.6.4 Merck KGaA Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.6.5 Merck KGaA Recent Developments

7.7 EUROAPI

7.7.1 EUROAPI Profile

7.7.2 EUROAPI Main Business

7.7.3 EUROAPI Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.7.4 EUROAPI Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.7.5 EUROAPI Recent Developments

7.8 CordenPharma

7.8.1 CordenPharma Profile

7.8.2 CordenPharma Main Business

7.8.3 CordenPharma Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.8.4 CordenPharma Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.8.5 CordenPharma Recent Developments

7.9 Cytiva

7.9.1 Cytiva Profile

7.9.2 Cytiva Main Business

7.9.3 Cytiva Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.9.4 Cytiva Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.9.5 Cytiva Recent Developments

7.10 TriLink BioTechnologies

7.10.1 TriLink BioTechnologies Profile

7.10.2 TriLink BioTechnologies Main Business

7.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.10.4 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.10.5 TriLink BioTechnologies Recent Developments

7.11 Medicilon

7.11.1 Medicilon Profile

7.11.2 Medicilon Main Business

7.11.3 Medicilon Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.11.4 Medicilon Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.11.5 Medicilon Recent Developments

7.12 General Biol

7.12.1 General Biol Profile

7.12.2 General Biol Main Business

7.12.3 General Biol Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.12.4 General Biol Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.12.5 General Biol Recent Developments

7.13 BioSpring

7.13.1 BioSpring Profile

7.13.2 BioSpring Main Business

7.13.3 BioSpring Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.13.4 BioSpring Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.13.5 BioSpring Recent Developments

7.14 Bio-Synthesis Inc

7.14.1 Bio-Synthesis Inc Profile

7.14.2 Bio-Synthesis Inc Main Business

7.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.14.4 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.14.5 Bio-Synthesis Inc Recent Developments

7.15 Aurisco

7.15.1 Aurisco Profile

7.15.2 Aurisco Main Business

7.15.3 Aurisco Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.15.4 Aurisco Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.15.5 Aurisco Recent Developments

7.16 Suzhou Olipharma Co.,Ltd

7.16.1 Suzhou Olipharma Co.,Ltd Profile

7.16.2 Suzhou Olipharma Co.,Ltd Main Business

7.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.16.4 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.16.5 Suzhou Olipharma Co.,Ltd Recent Developments

7.17 Porton

7.17.1 Porton Profile

7.17.2 Porton Main Business

7.17.3 Porton Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.17.4 Porton Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.17.5 Porton Recent Developments

7.18 RIBOPharm

7.18.1 RIBOPharm Profile

7.18.2 RIBOPharm Main Business

7.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Products, Services and Solutions

7.18.4 RIBOPharm Oligonucleotide Drug CDMO Services Revenue (US$ Million) & (2020-2025)

7.18.5 RIBOPharm Recent Developments

8 Industry Chain Analysis

8.1 Oligonucleotide Drug CDMO Services Industrial Chain

8.2 Oligonucleotide Drug CDMO Services Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Oligonucleotide Drug CDMO Services Sales Model

8.5.2 Sales Channel

8.5.3 Oligonucleotide Drug CDMO Services Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Oligonucleotide Drug CDMO Services Market Trends

Table 2. Oligonucleotide Drug CDMO Services Market Drivers & Opportunity

Table 3. Oligonucleotide Drug CDMO Services Market Challenges

Table 4. Oligonucleotide Drug CDMO Services Market Restraints

Table 5. Global Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Company (2020-2025)

Table 7. Key Companies Oligonucleotide Drug CDMO Services Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Oligonucleotide Drug CDMO Services Product Type

Table 9. Key Companies Time to Begin Mass Production of Oligonucleotide Drug CDMO Services

Table 10. Global Oligonucleotide Drug CDMO Services Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drug CDMO Services as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Oligonucleotide Drug CDMO Services Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global Oligonucleotide Drug CDMO Services Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global Oligonucleotide Drug CDMO Services Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global Oligonucleotide Drug CDMO Services Sales Market Share in Value by Type (2020-2025)

Table 17. Global Oligonucleotide Drug CDMO Services Sales Market Share in Value by Type (2026-2031)

Table 18. Global Oligonucleotide Drug CDMO Services Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global Oligonucleotide Drug CDMO Services Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global Oligonucleotide Drug CDMO Services Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global Oligonucleotide Drug CDMO Services Sales Market Share in Value by Application (2020-2025)

Table 22. Global Oligonucleotide Drug CDMO Services Sales Market Share in Value by Application (2026-2031)

Table 23. Global Oligonucleotide Drug CDMO Services Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global Oligonucleotide Drug CDMO Services Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global Oligonucleotide Drug CDMO Services Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global Oligonucleotide Drug CDMO Services Sales Value by Region (2020-2025) & (%)

Table 27. Global Oligonucleotide Drug CDMO Services Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions Oligonucleotide Drug CDMO Services Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions Oligonucleotide Drug CDMO Services Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions Oligonucleotide Drug CDMO Services Sales Value, (2026-2031) & (US$ Million)

Table 31. Bachem Basic Information List

Table 32. Bachem Description and Business Overview

Table 33. Bachem Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 34. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Bachem (2020-2025)

Table 35. Bachem Recent Developments

Table 36. WuXi TIDES Basic Information List

Table 37. WuXi TIDES Description and Business Overview

Table 38. WuXi TIDES Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 39. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of WuXi TIDES (2020-2025)

Table 40. WuXi TIDES Recent Developments

Table 41. Ajinomoto Co Basic Information List

Table 42. Ajinomoto Co Description and Business Overview

Table 43. Ajinomoto Co Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 44. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Ajinomoto Co (2020-2025)

Table 45. Ajinomoto Co Recent Developments

Table 46. Waters Basic Information List

Table 47. Waters Description and Business Overview

Table 48. Waters Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 49. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Waters (2020-2025)

Table 50. Waters Recent Developments

Table 51. AGC Biologics Basic Information List

Table 52. AGC Biologics Description and Business Overview

Table 53. AGC Biologics Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 54. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of AGC Biologics (2020-2025)

Table 55. AGC Biologics Recent Developments

Table 56. Merck KGaA Basic Information List

Table 57. Merck KGaA Description and Business Overview

Table 58. Merck KGaA Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 59. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Merck KGaA (2020-2025)

Table 60. Merck KGaA Recent Developments

Table 61. EUROAPI Basic Information List

Table 62. EUROAPI Description and Business Overview

Table 63. EUROAPI Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 64. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of EUROAPI (2020-2025)

Table 65. EUROAPI Recent Developments

Table 66. CordenPharma Basic Information List

Table 67. CordenPharma Description and Business Overview

Table 68. CordenPharma Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 69. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of CordenPharma (2020-2025)

Table 70. CordenPharma Recent Developments

Table 71. Cytiva Basic Information List

Table 72. Cytiva Description and Business Overview

Table 73. Cytiva Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 74. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Cytiva (2020-2025)

Table 75. Cytiva Recent Developments

Table 76. TriLink BioTechnologies Basic Information List

Table 77. TriLink BioTechnologies Description and Business Overview

Table 78. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 79. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of TriLink BioTechnologies (2020-2025)

Table 80. TriLink BioTechnologies Recent Developments

Table 81. Medicilon Basic Information List

Table 82. Medicilon Description and Business Overview

Table 83. Medicilon Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 84. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Medicilon (2020-2025)

Table 85. Medicilon Recent Developments

Table 86. General Biol Basic Information List

Table 87. General Biol Description and Business Overview

Table 88. General Biol Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 89. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of General Biol (2020-2025)

Table 90. General Biol Recent Developments

Table 91. BioSpring Basic Information List

Table 92. BioSpring Description and Business Overview

Table 93. BioSpring Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 94. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of BioSpring (2020-2025)

Table 95. BioSpring Recent Developments

Table 96. Bio-Synthesis Inc Basic Information List

Table 97. Bio-Synthesis Inc Description and Business Overview

Table 98. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 99. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Bio-Synthesis Inc (2020-2025)

Table 100. Bio-Synthesis Inc Recent Developments

Table 101. Aurisco Basic Information List

Table 102. Aurisco Description and Business Overview

Table 103. Aurisco Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 104. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Aurisco (2020-2025)

Table 105. Aurisco Recent Developments

Table 106. Suzhou Olipharma Co.,Ltd Basic Information List

Table 107. Suzhou Olipharma Co.,Ltd Description and Business Overview

Table 108. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 109. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Suzhou Olipharma Co.,Ltd (2020-2025)

Table 110. Suzhou Olipharma Co.,Ltd Recent Developments

Table 111. Porton Basic Information List

Table 112. Porton Description and Business Overview

Table 113. Porton Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 114. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of Porton (2020-2025)

Table 115. Porton Recent Developments

Table 116. RIBOPharm Basic Information List

Table 117. RIBOPharm Description and Business Overview

Table 118. RIBOPharm Oligonucleotide Drug CDMO Services Products, Services and Solutions

Table 119. Revenue (US$ Million) in Oligonucleotide Drug CDMO Services Business of RIBOPharm (2020-2025)

Table 120. RIBOPharm Recent Developments

Table 121. Key Raw Materials Lists

Table 122. Raw Materials Key Suppliers Lists

Table 123. Oligonucleotide Drug CDMO Services Downstream Customers

Table 124. Oligonucleotide Drug CDMO Services Distributors List

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

List of Figures

Figure 1. Oligonucleotide Drug CDMO Services Product Picture

Figure 2. Global Oligonucleotide Drug CDMO Services Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Oligonucleotide Drug CDMO Services Sales Value (2020-2031) & (US$ Million)

Figure 4. Oligonucleotide Drug CDMO Services Report Years Considered

Figure 5. Global Oligonucleotide Drug CDMO Services Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Oligonucleotide Drug CDMO Services Revenue in 2024

Figure 7. Oligonucleotide Drug CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. API Picture

Figure 9. Preparation Picture

Figure 10. Global Oligonucleotide Drug CDMO Services Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 11. Global Oligonucleotide Drug CDMO Services Sales Value Market Share by Type, 2024 & 2031

Figure 12. Product Picture of SME Pharmaceutical Company

Figure 13. Product Picture of Large Pharmaceutical Company

Figure 14. Global Oligonucleotide Drug CDMO Services Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 15. Global Oligonucleotide Drug CDMO Services Sales Value Market Share by Application, 2024 & 2031

Figure 16. North America Oligonucleotide Drug CDMO Services Sales Value (2020-2031) & (US$ Million)

Figure 17. North America Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

Figure 18. Europe Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 19. Europe Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

Figure 20. Asia Pacific Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 21. Asia Pacific Oligonucleotide Drug CDMO Services Sales Value by Region (%), 2024 VS 2031

Figure 22. South America Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 23. South America Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

Figure 24. Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 25. Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value by Country (%), 2024 VS 2031

Figure 26. Key Countries/Regions Oligonucleotide Drug CDMO Services Sales Value (%), (2020-2031)

Figure 27. United States Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 28. United States Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

Figure 29. United States Oligonucleotide Drug CDMO Services Sales Value by Application (%), 2024 VS 2031

Figure 30. Europe Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 31. Europe Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

Figure 32. Europe Oligonucleotide Drug CDMO Services Sales Value by Application (%), 2024 VS 2031

Figure 33. China Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 34. China Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

Figure 35. China Oligonucleotide Drug CDMO Services Sales Value by Application (%), 2024 VS 2031

Figure 36. Japan Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 37. Japan Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

Figure 38. Japan Oligonucleotide Drug CDMO Services Sales Value by Application (%), 2024 VS 2031

Figure 39. South Korea Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 40. South Korea Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

Figure 41. South Korea Oligonucleotide Drug CDMO Services Sales Value by Application (%), 2024 VS 2031

Figure 42. Southeast Asia Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 43. Southeast Asia Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

Figure 44. Southeast Asia Oligonucleotide Drug CDMO Services Sales Value by Application (%), 2024 VS 2031

Figure 45. India Oligonucleotide Drug CDMO Services Sales Value, (2020-2031) & (US$ Million)

Figure 46. India Oligonucleotide Drug CDMO Services Sales Value by Type (%), 2024 VS 2031

Figure 47. India Oligonucleotide Drug CDMO Services Sales Value by Application (%), 2024 VS 2031

Figure 48. Oligonucleotide Drug CDMO Services Industrial Chain

Figure 49. Oligonucleotide Drug CDMO Services Manufacturing Cost Structure

Figure 50. Channels of Distribution (Direct Sales, and Distribution)

Figure 51. Bottom-up and Top-down Approaches for This Report

Figure 52. Data Triangulation

Figure 53. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Oligonucleotide Drug CDMO Services market? zhanKai

The top companies in the global Oligonucleotide Drug CDMO Services market are Bachem、WuXi TIDES、Ajinomoto Co.

Related Reports

Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 146
USD 4900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 107
USD 4250.00
(Single User License)
Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-08
Pages: 135
USD 3950.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2026
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-08
Pages: 122
USD 2900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 106
USD 4250.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 158
USD 4900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2025
The global market for Oligonucleotide Drug CDMO Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-03-12
Pages: 99
USD 2900.00
(Single User License)
Global and United States Oligonucleotide Drug CDMO Services Market Report & Forecast 2024-2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 127
USD 4350.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 99
USD 2900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Insights, Forecast to 2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 152
USD 4900.00
(Single User License)

Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 146
USD 4900.00 (Single User License)
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 107
USD 4250.00 (Single User License)
Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-01-08
Pages: 135
USD 3950.00 (Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2026
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-08
Pages: 122
USD 2900.00 (Single User License)
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 106
USD 4250.00 (Single User License)
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 158
USD 4900.00 (Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2025
The global market for Oligonucleotide Drug CDMO Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-03-12
Pages: 99
USD 2900.00 (Single User License)
Global and United States Oligonucleotide Drug CDMO Services Market Report & Forecast 2024-2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 127
USD 4350.00 (Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 99
USD 2900.00 (Single User License)
Global Oligonucleotide Drug CDMO Services Market Insights, Forecast to 2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 152
USD 4900.00 (Single User License)